nodes	percent_of_prediction	percent_of_DWPC	metapath
Montelukast—CYP2C8—Sorafenib—thyroid cancer	0.088	0.331	CbGbCtD
Montelukast—CYP2C9—Sorafenib—thyroid cancer	0.0614	0.231	CbGbCtD
Montelukast—CYP3A4—Vandetanib—thyroid cancer	0.0592	0.223	CbGbCtD
Montelukast—ALOX5—Synthesis of Lipoxins (LX)—HPGD—thyroid cancer	0.0561	0.219	CbGpPWpGaD
Montelukast—ALOX5—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.0379	0.148	CbGpPWpGaD
Montelukast—CYP3A4—Sorafenib—thyroid cancer	0.0357	0.134	CbGbCtD
Montelukast—CYP3A4—Doxorubicin—thyroid cancer	0.0217	0.0814	CbGbCtD
Montelukast—PTGS1—Eicosanoid Synthesis—PTGES2—thyroid cancer	0.0164	0.0641	CbGpPWpGaD
Montelukast—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—HPGD—thyroid cancer	0.0124	0.0482	CbGpPWpGaD
Montelukast—ALOX5—Arachidonic acid metabolism—HPGD—thyroid cancer	0.0103	0.0401	CbGpPWpGaD
Montelukast—SLCO2B1—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00749	0.0292	CbGpPWpGaD
Montelukast—PTGS1—Prostaglandin Synthesis and Regulation—HPGD—thyroid cancer	0.00671	0.0262	CbGpPWpGaD
Montelukast—PTGS1—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00446	0.0174	CbGpPWpGaD
Montelukast—Erythema nodosum—Doxorubicin—thyroid cancer	0.00402	0.00842	CcSEcCtD
Montelukast—Hepatobiliary disease—Vandetanib—thyroid cancer	0.00399	0.00835	CcSEcCtD
Montelukast—Epistaxis—Vandetanib—thyroid cancer	0.00398	0.00833	CcSEcCtD
Montelukast—Sinusitis—Vandetanib—thyroid cancer	0.00396	0.00828	CcSEcCtD
Montelukast—Urinary tract disorder—Vandetanib—thyroid cancer	0.00374	0.00783	CcSEcCtD
Montelukast—Urethral disorder—Vandetanib—thyroid cancer	0.00371	0.00777	CcSEcCtD
Montelukast—Erythema multiforme—Vandetanib—thyroid cancer	0.00358	0.00749	CcSEcCtD
Montelukast—Cardiac disorder—Vandetanib—thyroid cancer	0.00351	0.00735	CcSEcCtD
Montelukast—Mediastinal disorder—Vandetanib—thyroid cancer	0.00341	0.00714	CcSEcCtD
Montelukast—Aspartate aminotransferase increased—Sorafenib—thyroid cancer	0.00332	0.00696	CcSEcCtD
Montelukast—Toxic epidermal necrolysis—Sorafenib—thyroid cancer	0.00332	0.00696	CcSEcCtD
Montelukast—ALOX5—Eicosanoid Synthesis—PTGS2—thyroid cancer	0.00332	0.0129	CbGpPWpGaD
Montelukast—Mental disorder—Vandetanib—thyroid cancer	0.00332	0.00694	CcSEcCtD
Montelukast—Nasopharyngitis—Sorafenib—thyroid cancer	0.0033	0.00691	CcSEcCtD
Montelukast—Alanine aminotransferase increased—Sorafenib—thyroid cancer	0.00325	0.00681	CcSEcCtD
Montelukast—Muscle spasms—Vandetanib—thyroid cancer	0.00317	0.00663	CcSEcCtD
Montelukast—Pancreatitis—Sorafenib—thyroid cancer	0.00313	0.00655	CcSEcCtD
Montelukast—Tremor—Vandetanib—thyroid cancer	0.00309	0.00646	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—CALCB—thyroid cancer	0.00289	0.0113	CbGpPWpGaD
Montelukast—CYP2C8—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00288	0.0112	CbGpPWpGaD
Montelukast—Cough—Vandetanib—thyroid cancer	0.00287	0.00602	CcSEcCtD
Montelukast—Pneumonia—Sorafenib—thyroid cancer	0.00286	0.00599	CcSEcCtD
Montelukast—Convulsion—Vandetanib—thyroid cancer	0.00285	0.00598	CcSEcCtD
Montelukast—Infestation NOS—Sorafenib—thyroid cancer	0.00284	0.00595	CcSEcCtD
Montelukast—Infestation—Sorafenib—thyroid cancer	0.00284	0.00595	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Sorafenib—thyroid cancer	0.00282	0.0059	CcSEcCtD
Montelukast—Arthralgia—Vandetanib—thyroid cancer	0.0028	0.00587	CcSEcCtD
Montelukast—Anxiety—Vandetanib—thyroid cancer	0.0028	0.00585	CcSEcCtD
Montelukast—Neuropathy peripheral—Sorafenib—thyroid cancer	0.00279	0.00584	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Vandetanib—thyroid cancer	0.00279	0.00583	CcSEcCtD
Montelukast—Jaundice—Sorafenib—thyroid cancer	0.00277	0.0058	CcSEcCtD
Montelukast—Hepatobiliary disease—Sorafenib—thyroid cancer	0.00269	0.00563	CcSEcCtD
Montelukast—Oedema—Vandetanib—thyroid cancer	0.00269	0.00563	CcSEcCtD
Montelukast—Epistaxis—Sorafenib—thyroid cancer	0.00268	0.00562	CcSEcCtD
Montelukast—Infection—Vandetanib—thyroid cancer	0.00267	0.00559	CcSEcCtD
Montelukast—Nervous system disorder—Vandetanib—thyroid cancer	0.00264	0.00552	CcSEcCtD
Montelukast—Thrombocytopenia—Vandetanib—thyroid cancer	0.00263	0.00551	CcSEcCtD
Montelukast—Skin disorder—Vandetanib—thyroid cancer	0.00261	0.00547	CcSEcCtD
Montelukast—Laryngitis—Epirubicin—thyroid cancer	0.00261	0.00546	CcSEcCtD
Montelukast—Dermatitis atopic—Epirubicin—thyroid cancer	0.00254	0.00531	CcSEcCtD
Montelukast—Urinary tract disorder—Sorafenib—thyroid cancer	0.00252	0.00528	CcSEcCtD
Montelukast—Connective tissue disorder—Sorafenib—thyroid cancer	0.00251	0.00525	CcSEcCtD
Montelukast—Urethral disorder—Sorafenib—thyroid cancer	0.0025	0.00524	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Vandetanib—thyroid cancer	0.00245	0.00513	CcSEcCtD
Montelukast—Insomnia—Vandetanib—thyroid cancer	0.00243	0.00509	CcSEcCtD
Montelukast—Paraesthesia—Vandetanib—thyroid cancer	0.00241	0.00506	CcSEcCtD
Montelukast—Erythema multiforme—Sorafenib—thyroid cancer	0.00241	0.00505	CcSEcCtD
Montelukast—Otitis media—Epirubicin—thyroid cancer	0.00241	0.00505	CcSEcCtD
Montelukast—Laryngitis—Doxorubicin—thyroid cancer	0.00241	0.00505	CcSEcCtD
Montelukast—Cardiac disorder—Sorafenib—thyroid cancer	0.00237	0.00496	CcSEcCtD
Montelukast—Dyspepsia—Vandetanib—thyroid cancer	0.00237	0.00496	CcSEcCtD
Montelukast—CYP2A6—Fluoropyrimidine Activity—SMUG1—thyroid cancer	0.00237	0.00922	CbGpPWpGaD
Montelukast—Dermatitis atopic—Doxorubicin—thyroid cancer	0.00235	0.00492	CcSEcCtD
Montelukast—CYP2C9—Arachidonic acid metabolism—HPGD—thyroid cancer	0.00235	0.00914	CbGpPWpGaD
Montelukast—Gastrointestinal disorder—Vandetanib—thyroid cancer	0.00232	0.00486	CcSEcCtD
Montelukast—Fatigue—Vandetanib—thyroid cancer	0.00232	0.00485	CcSEcCtD
Montelukast—Immune system disorder—Sorafenib—thyroid cancer	0.00231	0.00483	CcSEcCtD
Montelukast—Mediastinal disorder—Sorafenib—thyroid cancer	0.0023	0.00482	CcSEcCtD
Montelukast—Pain—Vandetanib—thyroid cancer	0.0023	0.00481	CcSEcCtD
Montelukast—Mental disorder—Sorafenib—thyroid cancer	0.00224	0.00468	CcSEcCtD
Montelukast—Otitis media—Doxorubicin—thyroid cancer	0.00223	0.00468	CcSEcCtD
Montelukast—Liver injury—Epirubicin—thyroid cancer	0.00223	0.00467	CcSEcCtD
Montelukast—PTGS1—Synthesis of Prostaglandins (PG) and Thromboxanes (TX)—PTGS2—thyroid cancer	0.00222	0.00864	CbGpPWpGaD
Montelukast—Gastrointestinal pain—Vandetanib—thyroid cancer	0.0022	0.0046	CcSEcCtD
Montelukast—CYP2A6—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00218	0.00849	CbGpPWpGaD
Montelukast—Muscle spasms—Sorafenib—thyroid cancer	0.00214	0.00447	CcSEcCtD
Montelukast—Abdominal pain—Vandetanib—thyroid cancer	0.00213	0.00445	CcSEcCtD
Montelukast—Body temperature increased—Vandetanib—thyroid cancer	0.00213	0.00445	CcSEcCtD
Montelukast—Bone disorder—Epirubicin—thyroid cancer	0.00208	0.00436	CcSEcCtD
Montelukast—Viral infection—Epirubicin—thyroid cancer	0.00208	0.00436	CcSEcCtD
Montelukast—Liver injury—Doxorubicin—thyroid cancer	0.00207	0.00433	CcSEcCtD
Montelukast—Angioedema—Sorafenib—thyroid cancer	0.00203	0.00425	CcSEcCtD
Montelukast—CYP3A4—Liver X Receptor Pathway—RXRA—thyroid cancer	0.00203	0.00789	CbGpPWpGaD
Montelukast—Cough—Sorafenib—thyroid cancer	0.00194	0.00406	CcSEcCtD
Montelukast—Asthenia—Vandetanib—thyroid cancer	0.00193	0.00404	CcSEcCtD
Montelukast—Viral infection—Doxorubicin—thyroid cancer	0.00192	0.00403	CcSEcCtD
Montelukast—Bone disorder—Doxorubicin—thyroid cancer	0.00192	0.00403	CcSEcCtD
Montelukast—Pruritus—Vandetanib—thyroid cancer	0.0019	0.00398	CcSEcCtD
Montelukast—Myalgia—Sorafenib—thyroid cancer	0.00189	0.00396	CcSEcCtD
Montelukast—Arthralgia—Sorafenib—thyroid cancer	0.00189	0.00396	CcSEcCtD
Montelukast—CYP2A6—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—PTGS2—thyroid cancer	0.00188	0.00734	CbGpPWpGaD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Sorafenib—thyroid cancer	0.00188	0.00393	CcSEcCtD
Montelukast—Hepatocellular injury—Epirubicin—thyroid cancer	0.00188	0.00393	CcSEcCtD
Montelukast—ALOX5—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.00185	0.0072	CbGpPWpGaD
Montelukast—Diarrhoea—Vandetanib—thyroid cancer	0.00184	0.00385	CcSEcCtD
Montelukast—Anaphylactic shock—Sorafenib—thyroid cancer	0.00181	0.0038	CcSEcCtD
Montelukast—Infection—Sorafenib—thyroid cancer	0.0018	0.00377	CcSEcCtD
Montelukast—Nervous system disorder—Sorafenib—thyroid cancer	0.00178	0.00372	CcSEcCtD
Montelukast—Dizziness—Vandetanib—thyroid cancer	0.00178	0.00372	CcSEcCtD
Montelukast—Thrombocytopenia—Sorafenib—thyroid cancer	0.00178	0.00372	CcSEcCtD
Montelukast—Neuropathy—Epirubicin—thyroid cancer	0.00176	0.00369	CcSEcCtD
Montelukast—Skin disorder—Sorafenib—thyroid cancer	0.00176	0.00369	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—TSHR—thyroid cancer	0.00176	0.00685	CbGpPWpGaD
Montelukast—Hepatocellular injury—Doxorubicin—thyroid cancer	0.00174	0.00364	CcSEcCtD
Montelukast—PTGS1—Overview of nanoparticle effects—PTGS2—thyroid cancer	0.00174	0.00677	CbGpPWpGaD
Montelukast—Vomiting—Vandetanib—thyroid cancer	0.00171	0.00358	CcSEcCtD
Montelukast—Rash—Vandetanib—thyroid cancer	0.0017	0.00355	CcSEcCtD
Montelukast—Dermatitis—Vandetanib—thyroid cancer	0.00169	0.00355	CcSEcCtD
Montelukast—Headache—Vandetanib—thyroid cancer	0.00168	0.00353	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Sorafenib—thyroid cancer	0.00165	0.00346	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—CALCB—thyroid cancer	0.00163	0.00637	CbGpPWpGaD
Montelukast—Neuropathy—Doxorubicin—thyroid cancer	0.00163	0.00342	CcSEcCtD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—CDK1—thyroid cancer	0.00161	0.00627	CbGpPWpGaD
Montelukast—Nausea—Vandetanib—thyroid cancer	0.0016	0.00334	CcSEcCtD
Montelukast—Dyspepsia—Sorafenib—thyroid cancer	0.0016	0.00334	CcSEcCtD
Montelukast—Gastrointestinal disorder—Sorafenib—thyroid cancer	0.00157	0.00328	CcSEcCtD
Montelukast—Fatigue—Sorafenib—thyroid cancer	0.00156	0.00327	CcSEcCtD
Montelukast—Pain—Sorafenib—thyroid cancer	0.00155	0.00325	CcSEcCtD
Montelukast—Eczema—Epirubicin—thyroid cancer	0.00152	0.00318	CcSEcCtD
Montelukast—CYSLTR1—Signaling by GPCR—CALCB—thyroid cancer	0.00148	0.00578	CbGpPWpGaD
Montelukast—Gastrointestinal pain—Sorafenib—thyroid cancer	0.00148	0.00311	CcSEcCtD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.00147	0.00573	CbGpPWpGaD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—TPR—thyroid cancer	0.00147	0.00572	CbGpPWpGaD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—CP—thyroid cancer	0.00147	0.00572	CbGpPWpGaD
Montelukast—Urticaria—Sorafenib—thyroid cancer	0.00144	0.00302	CcSEcCtD
Montelukast—PTGS1—Eicosanoid Synthesis—PTGS2—thyroid cancer	0.00144	0.00561	CbGpPWpGaD
Montelukast—Abdominal pain—Sorafenib—thyroid cancer	0.00143	0.003	CcSEcCtD
Montelukast—Body temperature increased—Sorafenib—thyroid cancer	0.00143	0.003	CcSEcCtD
Montelukast—Eczema—Doxorubicin—thyroid cancer	0.0014	0.00294	CcSEcCtD
Montelukast—CYSLTR1—Class A/1 (Rhodopsin-like receptors)—SST—thyroid cancer	0.00137	0.00533	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR ligand binding—TSHR—thyroid cancer	0.00134	0.00522	CbGpPWpGaD
Montelukast—Hypersensitivity—Sorafenib—thyroid cancer	0.00134	0.0028	CcSEcCtD
Montelukast—CYP2A6—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.00132	0.00513	CbGpPWpGaD
Montelukast—CYP2C8—Metapathway biotransformation—CHST14—thyroid cancer	0.00131	0.00512	CbGpPWpGaD
Montelukast—Asthenia—Sorafenib—thyroid cancer	0.0013	0.00272	CcSEcCtD
Montelukast—Pruritus—Sorafenib—thyroid cancer	0.00128	0.00269	CcSEcCtD
Montelukast—Diarrhoea—Sorafenib—thyroid cancer	0.00124	0.0026	CcSEcCtD
Montelukast—Toxic epidermal necrolysis—Epirubicin—thyroid cancer	0.00123	0.00257	CcSEcCtD
Montelukast—Aspartate aminotransferase increased—Epirubicin—thyroid cancer	0.00123	0.00257	CcSEcCtD
Montelukast—Nasopharyngitis—Epirubicin—thyroid cancer	0.00122	0.00255	CcSEcCtD
Montelukast—CYP3A4—Farnesoid X Receptor  Pathway—RXRA—thyroid cancer	0.00121	0.00472	CbGpPWpGaD
Montelukast—CYP2C9—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.00121	0.00472	CbGpPWpGaD
Montelukast—PTGS1—Prostaglandin Synthesis and Regulation—PTGS2—thyroid cancer	0.0012	0.0047	CbGpPWpGaD
Montelukast—Alanine aminotransferase increased—Epirubicin—thyroid cancer	0.0012	0.00252	CcSEcCtD
Montelukast—Dizziness—Sorafenib—thyroid cancer	0.0012	0.00251	CcSEcCtD
Montelukast—Asthma—Epirubicin—thyroid cancer	0.00118	0.00247	CcSEcCtD
Montelukast—Influenza—Epirubicin—thyroid cancer	0.00118	0.00247	CcSEcCtD
Montelukast—ALOX5—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.00117	0.00458	CbGpPWpGaD
Montelukast—Eosinophilia—Epirubicin—thyroid cancer	0.00117	0.00244	CcSEcCtD
Montelukast—Pancreatitis—Epirubicin—thyroid cancer	0.00116	0.00242	CcSEcCtD
Montelukast—Vomiting—Sorafenib—thyroid cancer	0.00115	0.00241	CcSEcCtD
Montelukast—Rash—Sorafenib—thyroid cancer	0.00114	0.00239	CcSEcCtD
Montelukast—Dermatitis—Sorafenib—thyroid cancer	0.00114	0.00239	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—PTCH1—thyroid cancer	0.00114	0.00444	CbGpPWpGaD
Montelukast—Toxic epidermal necrolysis—Doxorubicin—thyroid cancer	0.00114	0.00238	CcSEcCtD
Montelukast—Aspartate aminotransferase increased—Doxorubicin—thyroid cancer	0.00114	0.00238	CcSEcCtD
Montelukast—Headache—Sorafenib—thyroid cancer	0.00114	0.00238	CcSEcCtD
Montelukast—Bronchitis—Epirubicin—thyroid cancer	0.00113	0.00237	CcSEcCtD
Montelukast—PTGS1—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00113	0.0044	CbGpPWpGaD
Montelukast—Nasopharyngitis—Doxorubicin—thyroid cancer	0.00113	0.00236	CcSEcCtD
Montelukast—CYSLTR1—Endothelins—HRAS—thyroid cancer	0.00113	0.00439	CbGpPWpGaD
Montelukast—Alanine aminotransferase increased—Doxorubicin—thyroid cancer	0.00111	0.00233	CcSEcCtD
Montelukast—SLCO2B1—SLC-mediated transmembrane transport—SLC5A5—thyroid cancer	0.0011	0.00428	CbGpPWpGaD
Montelukast—Upper respiratory tract infection—Epirubicin—thyroid cancer	0.0011	0.00229	CcSEcCtD
Montelukast—Influenza—Doxorubicin—thyroid cancer	0.00109	0.00228	CcSEcCtD
Montelukast—Asthma—Doxorubicin—thyroid cancer	0.00109	0.00228	CcSEcCtD
Montelukast—Eosinophilia—Doxorubicin—thyroid cancer	0.00108	0.00226	CcSEcCtD
Montelukast—Nausea—Sorafenib—thyroid cancer	0.00108	0.00226	CcSEcCtD
Montelukast—Pancreatitis—Doxorubicin—thyroid cancer	0.00107	0.00224	CcSEcCtD
Montelukast—CYP2C9—Metapathway biotransformation—CHST14—thyroid cancer	0.00107	0.00416	CbGpPWpGaD
Montelukast—CYP2A6—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00107	0.00416	CbGpPWpGaD
Montelukast—Pneumonia—Epirubicin—thyroid cancer	0.00106	0.00221	CcSEcCtD
Montelukast—Infestation NOS—Epirubicin—thyroid cancer	0.00105	0.0022	CcSEcCtD
Montelukast—Infestation—Epirubicin—thyroid cancer	0.00105	0.0022	CcSEcCtD
Montelukast—Drowsiness—Epirubicin—thyroid cancer	0.00105	0.0022	CcSEcCtD
Montelukast—Bronchitis—Doxorubicin—thyroid cancer	0.00105	0.0022	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Epirubicin—thyroid cancer	0.00104	0.00218	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—SST—thyroid cancer	0.00104	0.00406	CbGpPWpGaD
Montelukast—Neuropathy peripheral—Epirubicin—thyroid cancer	0.00103	0.00216	CcSEcCtD
Montelukast—Jaundice—Epirubicin—thyroid cancer	0.00102	0.00214	CcSEcCtD
Montelukast—Conjunctivitis—Epirubicin—thyroid cancer	0.00102	0.00214	CcSEcCtD
Montelukast—ALOX5—Metabolism—MINPP1—thyroid cancer	0.00102	0.00396	CbGpPWpGaD
Montelukast—Upper respiratory tract infection—Doxorubicin—thyroid cancer	0.00101	0.00212	CcSEcCtD
Montelukast—CYSLTR1—GPCR ligand binding—CALCA—thyroid cancer	0.001	0.00391	CbGpPWpGaD
Montelukast—CYSLTR1—Endothelins—AKT1—thyroid cancer	0.000995	0.00388	CbGpPWpGaD
Montelukast—Hepatobiliary disease—Epirubicin—thyroid cancer	0.000994	0.00208	CcSEcCtD
Montelukast—Epistaxis—Epirubicin—thyroid cancer	0.000991	0.00208	CcSEcCtD
Montelukast—Sinusitis—Epirubicin—thyroid cancer	0.000986	0.00206	CcSEcCtD
Montelukast—Pneumonia—Doxorubicin—thyroid cancer	0.000978	0.00205	CcSEcCtD
Montelukast—Infestation NOS—Doxorubicin—thyroid cancer	0.000972	0.00204	CcSEcCtD
Montelukast—Infestation—Doxorubicin—thyroid cancer	0.000972	0.00204	CcSEcCtD
Montelukast—Drowsiness—Doxorubicin—thyroid cancer	0.000972	0.00204	CcSEcCtD
Montelukast—Stevens-Johnson syndrome—Doxorubicin—thyroid cancer	0.000964	0.00202	CcSEcCtD
Montelukast—Neuropathy peripheral—Doxorubicin—thyroid cancer	0.000953	0.002	CcSEcCtD
Montelukast—Jaundice—Doxorubicin—thyroid cancer	0.000948	0.00198	CcSEcCtD
Montelukast—Rhinitis—Epirubicin—thyroid cancer	0.000946	0.00198	CcSEcCtD
Montelukast—Conjunctivitis—Doxorubicin—thyroid cancer	0.000945	0.00198	CcSEcCtD
Montelukast—Hepatitis—Epirubicin—thyroid cancer	0.000944	0.00198	CcSEcCtD
Montelukast—Hypoaesthesia—Epirubicin—thyroid cancer	0.000939	0.00197	CcSEcCtD
Montelukast—Pharyngitis—Epirubicin—thyroid cancer	0.000936	0.00196	CcSEcCtD
Montelukast—Urinary tract disorder—Epirubicin—thyroid cancer	0.000932	0.00195	CcSEcCtD
Montelukast—Connective tissue disorder—Epirubicin—thyroid cancer	0.000927	0.00194	CcSEcCtD
Montelukast—Urethral disorder—Epirubicin—thyroid cancer	0.000925	0.00194	CcSEcCtD
Montelukast—Hepatobiliary disease—Doxorubicin—thyroid cancer	0.00092	0.00193	CcSEcCtD
Montelukast—Epistaxis—Doxorubicin—thyroid cancer	0.000917	0.00192	CcSEcCtD
Montelukast—Sinusitis—Doxorubicin—thyroid cancer	0.000912	0.00191	CcSEcCtD
Montelukast—CYP2C8—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.0009	0.00351	CbGpPWpGaD
Montelukast—Erythema multiforme—Epirubicin—thyroid cancer	0.000892	0.00187	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—CALCB—thyroid cancer	0.000877	0.00342	CbGpPWpGaD
Montelukast—Cardiac disorder—Epirubicin—thyroid cancer	0.000876	0.00183	CcSEcCtD
Montelukast—Rhinitis—Doxorubicin—thyroid cancer	0.000875	0.00183	CcSEcCtD
Montelukast—Hepatitis—Doxorubicin—thyroid cancer	0.000873	0.00183	CcSEcCtD
Montelukast—Hypoaesthesia—Doxorubicin—thyroid cancer	0.000869	0.00182	CcSEcCtD
Montelukast—Pharyngitis—Doxorubicin—thyroid cancer	0.000866	0.00181	CcSEcCtD
Montelukast—ALOX5—Metabolism—NDUFA13—thyroid cancer	0.000864	0.00337	CbGpPWpGaD
Montelukast—Urinary tract disorder—Doxorubicin—thyroid cancer	0.000862	0.00181	CcSEcCtD
Montelukast—Connective tissue disorder—Doxorubicin—thyroid cancer	0.000858	0.0018	CcSEcCtD
Montelukast—Urethral disorder—Doxorubicin—thyroid cancer	0.000856	0.00179	CcSEcCtD
Montelukast—Immune system disorder—Epirubicin—thyroid cancer	0.000852	0.00178	CcSEcCtD
Montelukast—Mediastinal disorder—Epirubicin—thyroid cancer	0.00085	0.00178	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—TRIM33—thyroid cancer	0.000831	0.00324	CbGpPWpGaD
Montelukast—Mental disorder—Epirubicin—thyroid cancer	0.000827	0.00173	CcSEcCtD
Montelukast—Erythema multiforme—Doxorubicin—thyroid cancer	0.000825	0.00173	CcSEcCtD
Montelukast—ALOX5—Metabolism—CHST14—thyroid cancer	0.000813	0.00317	CbGpPWpGaD
Montelukast—Cardiac disorder—Doxorubicin—thyroid cancer	0.00081	0.0017	CcSEcCtD
Montelukast—PTGS1—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000801	0.00312	CbGpPWpGaD
Montelukast—CYP3A4—Constitutive Androstane Receptor Pathway—RXRA—thyroid cancer	0.000799	0.00311	CbGpPWpGaD
Montelukast—Muscle spasms—Epirubicin—thyroid cancer	0.00079	0.00165	CcSEcCtD
Montelukast—Immune system disorder—Doxorubicin—thyroid cancer	0.000789	0.00165	CcSEcCtD
Montelukast—Mediastinal disorder—Doxorubicin—thyroid cancer	0.000787	0.00165	CcSEcCtD
Montelukast—CYP2A6—NRF2 pathway—SLC5A5—thyroid cancer	0.00077	0.003	CbGpPWpGaD
Montelukast—Mental disorder—Doxorubicin—thyroid cancer	0.000765	0.0016	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—TSHR—thyroid cancer	0.000757	0.00295	CbGpPWpGaD
Montelukast—Agitation—Epirubicin—thyroid cancer	0.000755	0.00158	CcSEcCtD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—TPR—thyroid cancer	0.000746	0.00291	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—CP—thyroid cancer	0.000746	0.00291	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—PRKAR1A—thyroid cancer	0.000734	0.00286	CbGpPWpGaD
Montelukast—CYP2C9—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000732	0.00285	CbGpPWpGaD
Montelukast—Muscle spasms—Doxorubicin—thyroid cancer	0.000731	0.00153	CcSEcCtD
Montelukast—CYP2C8—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.00073	0.00284	CbGpPWpGaD
Montelukast—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.000728	0.00284	CbGpPWpGaD
Montelukast—Palpitations—Epirubicin—thyroid cancer	0.000726	0.00152	CcSEcCtD
Montelukast—Cough—Epirubicin—thyroid cancer	0.000717	0.0015	CcSEcCtD
Montelukast—Convulsion—Epirubicin—thyroid cancer	0.000712	0.00149	CcSEcCtD
Montelukast—CYP3A4—Metapathway biotransformation—CHST14—thyroid cancer	0.000705	0.00275	CbGpPWpGaD
Montelukast—Myalgia—Epirubicin—thyroid cancer	0.000699	0.00146	CcSEcCtD
Montelukast—Arthralgia—Epirubicin—thyroid cancer	0.000699	0.00146	CcSEcCtD
Montelukast—Agitation—Doxorubicin—thyroid cancer	0.000698	0.00146	CcSEcCtD
Montelukast—Anxiety—Epirubicin—thyroid cancer	0.000697	0.00146	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—thyroid cancer	0.000694	0.00145	CcSEcCtD
Montelukast—CYSLTR1—Signaling by GPCR—TSHR—thyroid cancer	0.000687	0.00268	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—PRKAR1A—thyroid cancer	0.000676	0.00263	CbGpPWpGaD
Montelukast—Palpitations—Doxorubicin—thyroid cancer	0.000672	0.00141	CcSEcCtD
Montelukast—Anaphylactic shock—Epirubicin—thyroid cancer	0.00067	0.0014	CcSEcCtD
Montelukast—Oedema—Epirubicin—thyroid cancer	0.00067	0.0014	CcSEcCtD
Montelukast—Infection—Epirubicin—thyroid cancer	0.000666	0.00139	CcSEcCtD
Montelukast—Cough—Doxorubicin—thyroid cancer	0.000663	0.00139	CcSEcCtD
Montelukast—Convulsion—Doxorubicin—thyroid cancer	0.000658	0.00138	CcSEcCtD
Montelukast—Nervous system disorder—Epirubicin—thyroid cancer	0.000657	0.00138	CcSEcCtD
Montelukast—Thrombocytopenia—Epirubicin—thyroid cancer	0.000656	0.00137	CcSEcCtD
Montelukast—ALOX5—Metabolism—HPGD—thyroid cancer	0.000655	0.00255	CbGpPWpGaD
Montelukast—Skin disorder—Epirubicin—thyroid cancer	0.000651	0.00136	CcSEcCtD
Montelukast—Myalgia—Doxorubicin—thyroid cancer	0.000647	0.00135	CcSEcCtD
Montelukast—Arthralgia—Doxorubicin—thyroid cancer	0.000647	0.00135	CcSEcCtD
Montelukast—CYP2A6—NRF2 pathway—RXRA—thyroid cancer	0.000647	0.00252	CbGpPWpGaD
Montelukast—Anxiety—Doxorubicin—thyroid cancer	0.000645	0.00135	CcSEcCtD
Montelukast—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—thyroid cancer	0.000643	0.00135	CcSEcCtD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000638	0.00249	CbGpPWpGaD
Montelukast—CYP2A6—Fluoropyrimidine Activity—TP53—thyroid cancer	0.000628	0.00245	CbGpPWpGaD
Montelukast—Anaphylactic shock—Doxorubicin—thyroid cancer	0.00062	0.0013	CcSEcCtD
Montelukast—Oedema—Doxorubicin—thyroid cancer	0.00062	0.0013	CcSEcCtD
Montelukast—Infection—Doxorubicin—thyroid cancer	0.000616	0.00129	CcSEcCtD
Montelukast—Musculoskeletal discomfort—Epirubicin—thyroid cancer	0.000611	0.00128	CcSEcCtD
Montelukast—Nervous system disorder—Doxorubicin—thyroid cancer	0.000608	0.00127	CcSEcCtD
Montelukast—Thrombocytopenia—Doxorubicin—thyroid cancer	0.000607	0.00127	CcSEcCtD
Montelukast—Insomnia—Epirubicin—thyroid cancer	0.000606	0.00127	CcSEcCtD
Montelukast—Skin disorder—Doxorubicin—thyroid cancer	0.000602	0.00126	CcSEcCtD
Montelukast—Paraesthesia—Epirubicin—thyroid cancer	0.000602	0.00126	CcSEcCtD
Montelukast—PTGS1—Biological oxidations—RXRA—thyroid cancer	0.0006	0.00234	CbGpPWpGaD
Montelukast—Somnolence—Epirubicin—thyroid cancer	0.000596	0.00125	CcSEcCtD
Montelukast—CYP2C9—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000594	0.00231	CbGpPWpGaD
Montelukast—Dyspepsia—Epirubicin—thyroid cancer	0.00059	0.00124	CcSEcCtD
Montelukast—CYSLTR1—GPCR downstream signaling—SST—thyroid cancer	0.000588	0.00229	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—PTCH1—thyroid cancer	0.000584	0.00228	CbGpPWpGaD
Montelukast—Gastrointestinal disorder—Epirubicin—thyroid cancer	0.000579	0.00121	CcSEcCtD
Montelukast—Fatigue—Epirubicin—thyroid cancer	0.000578	0.00121	CcSEcCtD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—NRAS—thyroid cancer	0.000577	0.00225	CbGpPWpGaD
Montelukast—Pain—Epirubicin—thyroid cancer	0.000573	0.0012	CcSEcCtD
Montelukast—CYP2A6—Biological oxidations—RXRA—thyroid cancer	0.000567	0.00221	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—CALCA—thyroid cancer	0.000566	0.00221	CbGpPWpGaD
Montelukast—Musculoskeletal discomfort—Doxorubicin—thyroid cancer	0.000565	0.00118	CcSEcCtD
Montelukast—Insomnia—Doxorubicin—thyroid cancer	0.000561	0.00117	CcSEcCtD
Montelukast—CYP2A6—NRF2 pathway—NRG1—thyroid cancer	0.000559	0.00218	CbGpPWpGaD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—SLC5A5—thyroid cancer	0.000559	0.00218	CbGpPWpGaD
Montelukast—Paraesthesia—Doxorubicin—thyroid cancer	0.000557	0.00117	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—TCF7L1—thyroid cancer	0.000554	0.00216	CbGpPWpGaD
Montelukast—Somnolence—Doxorubicin—thyroid cancer	0.000551	0.00115	CcSEcCtD
Montelukast—Gastrointestinal pain—Epirubicin—thyroid cancer	0.000548	0.00115	CcSEcCtD
Montelukast—Dyspepsia—Doxorubicin—thyroid cancer	0.000546	0.00114	CcSEcCtD
Montelukast—Gastrointestinal disorder—Doxorubicin—thyroid cancer	0.000535	0.00112	CcSEcCtD
Montelukast—Fatigue—Doxorubicin—thyroid cancer	0.000535	0.00112	CcSEcCtD
Montelukast—CYSLTR1—Signaling by GPCR—SST—thyroid cancer	0.000534	0.00208	CbGpPWpGaD
Montelukast—Urticaria—Epirubicin—thyroid cancer	0.000533	0.00111	CcSEcCtD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000531	0.00207	CbGpPWpGaD
Montelukast—Pain—Doxorubicin—thyroid cancer	0.00053	0.00111	CcSEcCtD
Montelukast—Abdominal pain—Epirubicin—thyroid cancer	0.00053	0.00111	CcSEcCtD
Montelukast—Body temperature increased—Epirubicin—thyroid cancer	0.00053	0.00111	CcSEcCtD
Montelukast—CYP2C8—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000517	0.00202	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CALCA—thyroid cancer	0.000514	0.002	CbGpPWpGaD
Montelukast—PTGS1—Selenium Micronutrient Network—PTGS2—thyroid cancer	0.000509	0.00199	CbGpPWpGaD
Montelukast—Gastrointestinal pain—Doxorubicin—thyroid cancer	0.000507	0.00106	CcSEcCtD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—thyroid cancer	0.000497	0.00194	CbGpPWpGaD
Montelukast—Hypersensitivity—Epirubicin—thyroid cancer	0.000494	0.00103	CcSEcCtD
Montelukast—Urticaria—Doxorubicin—thyroid cancer	0.000493	0.00103	CcSEcCtD
Montelukast—Abdominal pain—Doxorubicin—thyroid cancer	0.00049	0.00103	CcSEcCtD
Montelukast—Body temperature increased—Doxorubicin—thyroid cancer	0.00049	0.00103	CcSEcCtD
Montelukast—CYP3A4—Cytochrome P450 - arranged by substrate type—RXRA—thyroid cancer	0.000483	0.00188	CbGpPWpGaD
Montelukast—Asthenia—Epirubicin—thyroid cancer	0.000481	0.00101	CcSEcCtD
Montelukast—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—thyroid cancer	0.00048	0.00187	CbGpPWpGaD
Montelukast—Pruritus—Epirubicin—thyroid cancer	0.000474	0.000993	CcSEcCtD
Montelukast—SLCO2B1—Transmembrane transport of small molecules—RXRA—thyroid cancer	0.000469	0.00183	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—CDK1—thyroid cancer	0.000466	0.00181	CbGpPWpGaD
Montelukast—Diarrhoea—Epirubicin—thyroid cancer	0.000459	0.00096	CcSEcCtD
Montelukast—Hypersensitivity—Doxorubicin—thyroid cancer	0.000457	0.000957	CcSEcCtD
Montelukast—Asthenia—Doxorubicin—thyroid cancer	0.000445	0.000932	CcSEcCtD
Montelukast—Dizziness—Epirubicin—thyroid cancer	0.000443	0.000928	CcSEcCtD
Montelukast—PTGS1—Metabolism—MINPP1—thyroid cancer	0.000441	0.00172	CbGpPWpGaD
Montelukast—Pruritus—Doxorubicin—thyroid cancer	0.000439	0.000919	CcSEcCtD
Montelukast—Vomiting—Epirubicin—thyroid cancer	0.000426	0.000892	CcSEcCtD
Montelukast—Diarrhoea—Doxorubicin—thyroid cancer	0.000424	0.000889	CcSEcCtD
Montelukast—Rash—Epirubicin—thyroid cancer	0.000423	0.000885	CcSEcCtD
Montelukast—Dermatitis—Epirubicin—thyroid cancer	0.000422	0.000884	CcSEcCtD
Montelukast—CYSLTR1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—thyroid cancer	0.000422	0.00165	CbGpPWpGaD
Montelukast—CYP2C9—Arachidonic acid metabolism—PTGS2—thyroid cancer	0.000421	0.00164	CbGpPWpGaD
Montelukast—Headache—Epirubicin—thyroid cancer	0.00042	0.000879	CcSEcCtD
Montelukast—CYP2A6—Metabolism—MINPP1—thyroid cancer	0.000417	0.00162	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000412	0.00161	CbGpPWpGaD
Montelukast—Dizziness—Doxorubicin—thyroid cancer	0.00041	0.000859	CcSEcCtD
Montelukast—CYSLTR1—Signaling Pathways—TSHR—thyroid cancer	0.000406	0.00158	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—PRKAR1A—thyroid cancer	0.000399	0.00156	CbGpPWpGaD
Montelukast—Nausea—Epirubicin—thyroid cancer	0.000398	0.000834	CcSEcCtD
Montelukast—Vomiting—Doxorubicin—thyroid cancer	0.000394	0.000826	CcSEcCtD
Montelukast—CYP3A4—Phase 1 - Functionalization of compounds—RXRA—thyroid cancer	0.000392	0.00153	CbGpPWpGaD
Montelukast—Rash—Doxorubicin—thyroid cancer	0.000391	0.000819	CcSEcCtD
Montelukast—Dermatitis—Doxorubicin—thyroid cancer	0.000391	0.000818	CcSEcCtD
Montelukast—Headache—Doxorubicin—thyroid cancer	0.000389	0.000814	CcSEcCtD
Montelukast—CYP2C8—Biological oxidations—RXRA—thyroid cancer	0.000388	0.00151	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—MEN1—thyroid cancer	0.000382	0.00149	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—TPR—thyroid cancer	0.000376	0.00147	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—NDUFA13—thyroid cancer	0.000375	0.00146	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PRKAR1A—thyroid cancer	0.00037	0.00144	CbGpPWpGaD
Montelukast—Nausea—Doxorubicin—thyroid cancer	0.000368	0.000771	CcSEcCtD
Montelukast—CYP2A6—Metabolism—NDUFA13—thyroid cancer	0.000354	0.00138	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—CHST14—thyroid cancer	0.000352	0.00137	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—PTCH1—thyroid cancer	0.000345	0.00135	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000335	0.00131	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—HPGD—thyroid cancer	0.000335	0.00131	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—CHST14—thyroid cancer	0.000333	0.0013	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—SST—thyroid cancer	0.000316	0.00123	CbGpPWpGaD
Montelukast—CYP2C9—Biological oxidations—RXRA—thyroid cancer	0.000315	0.00123	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CALCA—thyroid cancer	0.000304	0.00118	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—MINPP1—thyroid cancer	0.000285	0.00111	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—HPGD—thyroid cancer	0.000284	0.00111	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—SLC5A5—thyroid cancer	0.000282	0.0011	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CDK1—thyroid cancer	0.000275	0.00107	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—HPGD—thyroid cancer	0.000269	0.00105	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000264	0.00103	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—NDUFA13—thyroid cancer	0.000242	0.000944	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—RXRA—thyroid cancer	0.000237	0.000922	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—MINPP1—thyroid cancer	0.000232	0.000903	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.00023	0.000898	CbGpPWpGaD
Montelukast—ALOX5—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	0.00023	0.000897	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—CHST14—thyroid cancer	0.000228	0.000887	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—NRG1—thyroid cancer	0.000221	0.00086	CbGpPWpGaD
Montelukast—CYP3A4—Biological oxidations—RXRA—thyroid cancer	0.000208	0.000811	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TERT—thyroid cancer	0.000198	0.000773	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—NDUFA13—thyroid cancer	0.000197	0.000768	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—HIF1A—thyroid cancer	0.00019	0.000739	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—CHST14—thyroid cancer	0.000185	0.000722	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—HPGD—thyroid cancer	0.000183	0.000715	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—NRAS—thyroid cancer	0.000167	0.000651	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—TPR—thyroid cancer	0.000163	0.000636	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PRKAR1A—thyroid cancer	0.00016	0.000626	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—BRAF—thyroid cancer	0.000157	0.000612	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—TPR—thyroid cancer	0.000154	0.000601	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—MINPP1—thyroid cancer	0.000153	0.000596	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PRKAR1A—thyroid cancer	0.000152	0.000591	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PPARG—thyroid cancer	0.000149	0.000582	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—HPGD—thyroid cancer	0.000149	0.000582	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000149	0.00058	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	0.000145	0.000567	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—KRAS—thyroid cancer	0.000144	0.00056	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—NDUFA13—thyroid cancer	0.00013	0.000506	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—HRAS—thyroid cancer	0.000122	0.000476	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—CHST14—thyroid cancer	0.000122	0.000476	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—SLC5A5—thyroid cancer	0.000122	0.000476	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—RXRA—thyroid cancer	0.000121	0.000472	CbGpPWpGaD
Montelukast—CYSLTR1—GPCR downstream signaling—AKT1—thyroid cancer	0.000119	0.000463	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PTGS2—thyroid cancer	0.000118	0.000458	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—SLC5A5—thyroid cancer	0.000115	0.00045	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—CCND1—thyroid cancer	0.000115	0.000447	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	0.000114	0.000446	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—PTEN—thyroid cancer	0.000111	0.000431	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling by GPCR—AKT1—thyroid cancer	0.000108	0.00042	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—TPR—thyroid cancer	0.000105	0.000411	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PRKAR1A—thyroid cancer	0.000104	0.000404	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—RXRA—thyroid cancer	0.000103	0.0004	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—PTEN—thyroid cancer	0.000102	0.000399	CbGpPWpGaD
Montelukast—PTGS1—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	9.98e-05	0.000389	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—NRAS—thyroid cancer	9.86e-05	0.000384	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—HPGD—thyroid cancer	9.85e-05	0.000384	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—RXRA—thyroid cancer	9.7e-05	0.000378	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	9.4e-05	0.000366	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—TPR—thyroid cancer	8.58e-05	0.000334	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—KRAS—thyroid cancer	8.49e-05	0.000331	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PRKAR1A—thyroid cancer	8.44e-05	0.000329	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—SLC5A5—thyroid cancer	7.89e-05	0.000307	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—thyroid cancer	7.65e-05	0.000298	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—TP53—thyroid cancer	7.55e-05	0.000294	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	7.39e-05	0.000288	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—HRAS—thyroid cancer	7.22e-05	0.000281	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—RXRA—thyroid cancer	6.63e-05	0.000258	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PPARG—thyroid cancer	6.48e-05	0.000252	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	6.45e-05	0.000251	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—SLC5A5—thyroid cancer	6.42e-05	0.00025	CbGpPWpGaD
Montelukast—CYSLTR1—Signaling Pathways—AKT1—thyroid cancer	6.37e-05	0.000248	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PPARG—thyroid cancer	6.13e-05	0.000239	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—thyroid cancer	6.02e-05	0.000234	CbGpPWpGaD
Montelukast—ALOX5—Metabolism—AKT1—thyroid cancer	5.91e-05	0.00023	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—TPR—thyroid cancer	5.66e-05	0.00022	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PRKAR1A—thyroid cancer	5.56e-05	0.000217	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—RXRA—thyroid cancer	5.39e-05	0.00021	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—thyroid cancer	5.25e-05	0.000204	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PTGS2—thyroid cancer	5.1e-05	0.000199	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PTGS2—thyroid cancer	4.82e-05	0.000188	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—PTEN—thyroid cancer	4.44e-05	0.000173	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—SLC5A5—thyroid cancer	4.23e-05	0.000165	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—PTEN—thyroid cancer	4.2e-05	0.000164	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PPARG—thyroid cancer	4.18e-05	0.000163	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—RXRA—thyroid cancer	3.56e-05	0.000139	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PPARG—thyroid cancer	3.41e-05	0.000133	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PTGS2—thyroid cancer	3.29e-05	0.000128	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—PTEN—thyroid cancer	2.87e-05	0.000112	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PTGS2—thyroid cancer	2.68e-05	0.000104	CbGpPWpGaD
Montelukast—PTGS1—Metabolism—AKT1—thyroid cancer	2.56e-05	9.98e-05	CbGpPWpGaD
Montelukast—CYP2A6—Metabolism—AKT1—thyroid cancer	2.42e-05	9.44e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—PTEN—thyroid cancer	2.34e-05	9.11e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PPARG—thyroid cancer	2.25e-05	8.75e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PTGS2—thyroid cancer	1.77e-05	6.89e-05	CbGpPWpGaD
Montelukast—CYP2C8—Metabolism—AKT1—thyroid cancer	1.65e-05	6.45e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—PTEN—thyroid cancer	1.54e-05	6.01e-05	CbGpPWpGaD
Montelukast—CYP2C9—Metabolism—AKT1—thyroid cancer	1.35e-05	5.25e-05	CbGpPWpGaD
Montelukast—CYP3A4—Metabolism—AKT1—thyroid cancer	8.88e-06	3.46e-05	CbGpPWpGaD
